KOL | Sergey A LoparevDepartment of Urology, City Polyclinic № 3, Vladivostok, Russian Federation | Department of Urology, City Polyclinic № 3, Lugivaya 50, Vladivostok, Russian Federation | ... |
KOL Resume for Sergey A Loparev
| Year | |
|---|---|
| 2017 | Department of Urology, City Polyclinic № 3, Vladivostok, Russian Federation |
| 2016 | Sity Policlinic 3, Urological Department, Vladivostok, Russian Federation |
| 2015 | Department of Urology, City Polyclinic no. 3, Russian Federation |
| 2014 | Department of Urology, Sity policlinic 3, Vladivostok, Russian Federation, |
| 2013 | Department of Urology, City Polyclinic No. 3, Vladivostok, Russia. |
Sergey A Loparev: Influence Statistics
| Concept | World rank |
|---|---|
| а1 | #2 |
| lut state | #2 |
| combined high–dosed trospium | #2 |
| severe 158 symptoms | #2 |
| oab enables | #2 |
| dosed trospium | #2 |
| solifenacin depending | #2 |
| subgroup cycle therapy | #2 |
| trospium elderly patients | #2 |
| trospium elderly | #2 |
| subgroups severe symptoms | #2 |
| solifenacin 20 day | #2 |
| doubledosed antimuscarinics | #3 |
| years trospium | #3 |
| objective status markers | #3 |
| percentage noncompliant women | #3 |
| ≤005 pill | #3 |
| 2012 assignment | #3 |
| employers ⩽ | #3 |
| trospium 30 | #3 |
| compliance antimuscarinic | #3 |
| noncompliant women masri | #3 |
| day soilfenacin | #3 |
| ≤005 masri | #3 |
| lut studied | #3 |
| bmq 079 | #3 |
| bmq ≤005 | #3 |
| health ⩽ | #3 |
| benzilates diagnostic | #3 |
| average sample values | #3 |
| double doses trospium | #3 |
| soilfenacin 20 | #3 |
| patients stability treatment | #3 |
| standarddosed trospium | #3 |
| ≤005 correlation | #3 |
| women masri | #3 |
| medication adherence bmq | #3 |
| dosed antimuscarinic | #3 |
| age standarddosed trospium | #3 |
| tool uroflowmetry | #3 |
| uui lut | #3 |
| masri clinical | #3 |
| combined high‐dosed trospium | #3 |
| high‐dosed trospium | #3 |
| age doubledosed antimuscarinics | #3 |
| optimum masri cutoffs | #3 |
| groups 40–65 | #3 |
| age‐related aspect | #3 |
| ≤005 control points | #3 |
| trospium soilfenacin | #3 |
Open the FULL List in Excel | |
Prominent publications by Sergey A Loparev
OBJECTIVES: To study the effectiveness and safety of combined standard-dosed Solifenacin and Trospium for management of symptoms of overactive bladder (OAB) in elderly patients after the treatment with Tamsulosin.
PATIENTS AND METHODS: A total of 417 men over 50 years of age (average age 57.9 (8.3)) with diagnosed prostatic obstruction (score 8-19 according to I-PSS), who had not taken Tamsulosin before, were enrolled in the study. I-PSS questionnaire (from 8 to 19 - moderate) and ...
| Known for Oab Symptoms | Treatment Tamsulosin | Overactive Bladder | Prostatic Obstruction | Percentage Patients |
AIM: To study the cognitive functions and health-related quality of life (HRQoL) in individuals taking a combination of tamsulosin and solifenacin in a higher dosage.
METHODS: All patients (n = 262) were assigned to group A (N = 93, tamsulosin 0.4 mg + solifenacin 10 mg per day), group B (N = 83, tamsulosin 0.4 mg + solifenacin 20 mg), and control group C (N = 86; tamsulosin 0.4 mg + placebo). The lower urinary tract (LUT) condition was assessed on the scales International Prostate ...
| Known for Overactive Bladder | Tamsulosin Solifenacin | Prostatic Hyperplasia | Cognitive Functions | Healthrelated Quality Life |
OBJECTIVE: To increase the safety and effectiveness of treatments for overactive bladder (OAB) with moderate symptoms in elderly patients.
PATIENTS AND METHODS: Patients were examined at the Urodynamic Department of the Regional Diagnostic Center (Vladivostok, Russian Federation) from September 1, 2012 to December 31, 2012. The assignment of patients [n = 177, average age 69. 4 years, 98 women (55.4%) and 79 men (44.6%)] was random and blind in this placebo-controlled study. Patients ...
| Known for Overactive Bladder | Elderly Patients | Symptoms Oab | Trospium Solifenacin | Muscarinic Antagonists |
MATERIAL AND METHODS: 313 patients, 196 women and 117 men over 65 (average age 68.6) were included in this study. All patients underwent urodynamic examination before enrollment and after the study was completed. For clinical evaluation of LUT state ICIQ-SF questionnaires and bladder diaries were used. Patients with moderate (А, n = 155) and severe (В, n = 158) symptoms of OAB. Each group was divided into subgroups in which patients received Trospium 60 mg/day and Solifenacin 20 mg/day ...
| Known for Oab Symptoms | Elderly Patients | 1 Month | Bladder Diaries | Trospium Solifenacin |
Comparative effectiveness of combined high‐dosed Trospium and Solifenacin for severe OAB symptoms in age‐related aspect
[ PUBLICATION ]
Increase of effectiveness of treatment for severe overactive bladder (OAB) symptoms in patients 40–65 and 66–80 years of aged with combined antimuscarinic drugs. This placebo-controlled longitudinal study was performed on the basis of Regional Diagnostic Centre (Vladivostok city, Russian Federation) from 1 June 2011 to 30 December 2012. Assignment of patients (n = 299, average age: 67·1; women: 174 or 58·2%, men: 125 or 41·8%) was random blind. All patients were distributed into two age ...
| Known for 65 Years | Day Trospium | Overactive Bladder | Antimuscarinic Drugs | Severe Symptoms |
Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women
[ PUBLICATION ]
PURPOSE: To improve the long-term efficiency of the pharmacologic management of overactive bladder (OAB) in elderly women.
METHODS: The study comprised 229 women (mean age, 66.3 years; range, 65-77 years) with urodynamically and clinically confirmed OAB. All patients received the most effective treatment regimen based on the data obtained in the initial part of the study (trospium 60 mg/day + solifenacin 40 mg/day, for 6 weeks), and positive results similar to those in the first phase ...
| Known for Overactive Bladder | Elderly Women | Study Trospium | 1 Month | Treatment Oab |
PURPOSE: Study of validity of the Medication Adherence Self-Report Inventory (MASRI) for use in clinical practice to treat patients with benign prostatic obstruction (BPO) accompanied with overactive bladder (OAB) symptoms.
METHODS: During 12 weeks of the randomized study, 452 patients with BPO and OAB symptoms (mean age of 61.3 (12.7)) were studied for adherence to the treatment with Tamsulosin, Solifenacin and Trospium using the MASRI. External monitoring instruments included the Brief ...
| Known for Overactive Bladder | Benign Prostatic | Medication Adherence | Drug Therapy | Treatment Tamsulosin |
Objective: We studied the rationale for using standard and increased dosages of solifenacin and trospium against overactive bladder (OAB) symptoms of different severity among elderly patients. Methods: A total of 327 patients took part in the study: 199 women and 128 men older than 65 years (median age 69.1). The state of the lower urinary tracts was estimated by cystometry, ICIQ-SF and bladder diaries. Frequency of urgency urinary incontinence (UUI) was taken as a criterion of OAB ...
| Known for Overactive Bladder | Trospium Solifenacin | Severe Symptoms | Patients Moderate | 0001 Combination |
| Known for Overactive Bladder | Elderly Women | Dosed Antimuscarinics |
Comparison of objective and subjective factors in the adherence to antimuscarinics when treating overactive bladder in employed persons
[ PUBLICATION ]
Background: This study examines subjective reasons for the refusal of treatment and the state of objective status markers of various factors influencing the resistance of patients when treating overactive bladder by antimuscarinic drugs (AMs).
Methods: The socioeconomic and medical parameters were studied in 2465 patients aged 18-60 years (1446 women (58.7%), 1019 men (41.3%); mean age was 52.1) taking AMs during the year. The study control was carried out by studying passport data, ...
| Known for Overactive Bladder |
AimOur aim was to determine the efficiency of the Medication Compliance Self-Report Inventory (MASRI) in self-reporting antimuscarinic drug treatment compliance among women with urinary incontinence (UI).Materials and methodsThe study assessed 347 women aged 18–65 (averaging 49.7) years with more than one urinary incontinence (UI) episode per day. Treatment compliance was tested at the beginning and at weeks 4, 8, and 12 using the MASRI, the Brief Medication Questionnaire (BMQ), and ...
| Known for Medication Adherence |
Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial
[ PUBLICATION ]
AIM: The aim of this work was to study the factors affecting the stability of working patients in antimuscarinic (AM) drug treatment.
BACKGROUND: The prevalence of urge urinary incontinence (UUI) is an average of between 8.2% and 16.0% of the population. UUI is a condition that adversely affects the health-related quality of life. The first-line therapy in managing UUI is AM treatment.
METHODS: In 1006 patients between 18 and 60 years old (627 women, 379 men, mean age 69.4) who received ...
| Known for Lower Urinary Tract | Urinary Incontinence | Overactive Bladder | Influence Factors | Severe Symptoms |
Key People For Oab Symptoms
Sergey A Loparev:Expert Impact
Concepts for whichSergey A Loparevhas direct influence:Oab symptoms, Overactive bladder, Treatment compliance, Elderly women, Trospium solifenacin, Urinary incontinence, Antimuscarinic drugs, Patients 65 years.
Sergey A Loparev:KOL impact
Concepts related to the work of other authors for whichfor which Sergey A Loparev has influence:Overactive bladder, Medication adherence, Benign prostatic hyperplasia, Oab symptoms, Urinary incontinence, Elderly women, Measurement properties.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |